Predict your next investment

Calviri company logo
HEALTHCARE | Drug Discovery
calviri.com

See what CB Insights has to offer

Founded Year

2015

Stage

Unattributed - III | Alive

Total Raised

$12.14M

Last Raised

$5.15M | 1 mo ago

About Calviri

Calviri works to invent new approaches to creating personal and general cancer vaccines.

Calviri Headquarter Location

8606 S. Dorsey Lane

Tempe, Arizona, 85284,

United States

480-205-6436

Latest Calviri News

Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors

Nov 24, 2021

November 24, 2021 04:30 AM Eastern Standard Time ALACHUA, Fla.--( BUSINESS WIRE )--Lacerta Therapeutics, Inc. a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors. Dr. Min Wang has over 20 years of experience in the biotech space where she has operated as a business and legal advisor to the board and senior management at private and publicly traded companies through different phases of their organizational lifecycle. Dr. Wang most recently served as COO at Monte Rosa Therapeutics, where she held broad management responsibilities for key corporate functions. Previously, Dr. Wang served as COO of BlueRock Therapeutics through its acquisition by Bayer in 2019. Prior to BlueRock, Dr. Wang held the position of Senior VP, General Counsel and Corporate Secretary of Agios Pharmaceuticals. Earlier in her career, Dr. Wang served in roles of increasing responsibility in legal and IP functions at Genentech and Merck. Dr. Wang received her PhD in Organic Chemistry from Brown University and a JD from Fordham University School of Law. “Min’s extensive knowledge and expertise in drug and corporate development will serve Lacerta well as we look to become a leader in AAV-gene based therapies and we are privileged to welcome her to our board,” stated Edgar Rodriguez-Lebron, PhD, Lacerta’s President and CEO. Marc Wolff brings more than 23 years of experience in the life sciences industry in various management and finance leadership roles. Mr. Wolff is currently CEO at Calviri, a fully integrated healthcare company whose mission is to provide a broad spectrum of therapeutic vaccines and early diagnostics that prevent and treat cancer. Prior to joining Calviri, Mr. Wolff served as COO and CFO of Aldevron where he played a key role in scaling the company through exponential growth, enabling Aldevron’s clients to access essential GMP materials for their novel applications in gene and cell therapy. Prior to Aldevron, Mr. Wolff was EVP and CFO of Sancilio Pharmaceuticals, where he played a key role in leading the company through its IPO process in 2015. Mr. Wolff received his Master’s in Management and International Finance from Reims Management School. “We are very excited to have Marc join our board during this important time of accelerated growth and expansion at Lacerta,” said Dr. Rodriguez-Lebron. “His substantial knowledge and insight will be invaluable as we mature our platforms and begin to position ourselves in the market.” Dr. Wang and Mr. Wolff will join Dr. Jackson Streeter, Lacerta’s Chairman, Joe Zenkus, Senior Vice President at Sarepta Therapeutics and Dr. Rodriguez-Lebron on Lacerta’s Board. About Lacerta Therapeutics Lacerta Therapeutics, Inc. is focused on exploiting our proprietary capsid technology and scalable manufacturing platform to advance AAV-based therapies via three primary approaches: gene replacement, gene modulation and novel vectorization of antibodies. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Calviri

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Calviri is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Calviri Patents

Calviri has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/4/2017

11/9/2021

Vaccines, Clusters of differentiation, Immunology, Monoclonal antibodies, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/4/2017

00/00/0000

Grant Date

11/9/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Vaccines, Clusters of differentiation, Immunology, Monoclonal antibodies, Transcription factors

Subscribe to see more

Status

Grant

Subscribe to see more

Calviri Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Calviri Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.